van den Reek, Juul M. P. A.
van der Leest, Robert J. T.
Thomas, Sarah E. http://orcid.org/0000-0002-1343-353X
Prevoo, Ruud
Plantenga, Margreet E.
de Jong, Elke M. G. J. http://orcid.org/0000-0003-3872-5704
Clinical trials referenced in this document:
Documents that mention this clinical trial
Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands
https://doi.org/10.1007/s12325-023-02759-9
Funding for this research was provided by:
Amgen Inc.
Article History
Received: 3 October 2023
Accepted: 5 December 2023
First Online: 24 February 2024
Declarations
:
: Juul M.P.A. van den Reek: Carried out clinical trials for AbbVie, Celgene, Almirall, and Janssen; has received speaking fees/attended advisory boards from AbbVie, Janssen, Bristol Myers Squibb, Almirall, LEO Pharma, Novartis, UCB, and Eli Lilly; received reimbursement for attending or chairing a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc) Nijmegen, the Netherlands. Robert J.T. van der Leest: Nothing to disclose. Sarah E. Thomas: Carries out clinical trials for Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc) Nijmegen, the Netherlands. Ruud Prevoo: Nothing to disclose. Margreet E. Plantenga: Employee of and stockholder in Amgen B.V. Elke M.G.J. de Jong: Received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Bristol Myers Squibb, Janssen Pharmaceutica, LEO Pharma, Lilly, Novartis, and UCB; ZonMw, KCE, NWO, the National Psoriasis Foundation USA, RUMC/VGZ and RUMC/SMK. Has been a consultant, paid speaker, and/or participated in research for AbbVie, Amgen, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, LEO Pharma, Sanofi, and UCB. All funding is not personal but goes to the Radboud University Medical Centre (Radboudumc), Nijmegen, the Netherlands.
: This study was approved by the Code Geneesmiddelenreclame (CGR) and performed in accordance with Volume 9A of the Rules Governing Medicinal Products in the European Union, the Gedragscode Geneesmiddelenreclame of the CGR, and good pharmacovigilance practice. The study was approved by a national central ethics committee for observational studies in the Netherlands. nWMO statement given by the Regionale Toetsingscommissie Patiëntgebonden Onderzoek (RTPO) located in Leeuwarden, Netherlands, Ref. no. RTPO 959. Dutch Clinical Research Foundation (DCRF) METC* 2015–119. All patients provided written informed consent before study initiation. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.